Drug
Lti 03
Lti 03: highest development phase Phase 2, developed by Rein Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Rein Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| LTI-03 NCT06968845 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) |
Latest
No recent events.
Follow Lti 03 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.